New Delhi: In a move that could make COVID treatment available to more than half of the world’s population, drugmaker Pfizer Inc. has signed a deal with a U.N.-backed group to allow other manufacturers to make its experimental COVID-19 pill.
Pfizer said it would grant a license for the antiviral pill to the Geneva-based Medicines Patent Pool, which would let generic drug companies produce the pill for use in 95 countries, making up about 53% of the world’s population, Pfizer said in a statement on Tuesday, according to news agency AP.
The deal excludes some large countries that have suffered devastating coronavirus outbreaks.
“It’s quite significant that we will be able to provide access to a drug that appears to be effective and has just been developed, to more than 4 billion people,” Esteban Burrone, head of policy at the Medicines Patent Pool was quoted as saying.
He estimated that other drugmakers would be able to start producing the pill within months, but acknowledged the agreement wouldn’t please everyone.
Under the terms of the agreement, Pfizer will not receive royalties on sales in low-income countries and will waive royalties on sales in all countries covered by the agreement while COVID-19 remains a public health emergency.
